Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective

Saved in:
Bibliographic Details
Published inTherapeutic delivery Vol. 11; no. 4; pp. 213 - 215
Main Authors Shukla, Snehal K, Gupta, Vivek
Format Journal Article
LanguageEnglish
Published England Newlands Press Ltd 01.04.2020
Subjects
Antineoplastic Agents - therapeutic use
Cell Line, Tumor
formulation approaches
Humans
Lung Neoplasms - drug therapy
nanocarriers
Nanotechnology - trends
non-small-cell lung cancer (NSCLC)
pulmonary delivery
sorafenib
Sorafenib - therapeutic use
tyrosine-kinase inhibitor
pulmonary delivery
formulation approaches
sorafenib
non-small-cell lung cancer (NSCLC)
tyrosine-kinase inhibitor
nanocarriers
Online AccessGet full text

Cover

Author Shukla, Snehal K
Gupta, Vivek
AuthorAffiliation 1College of Pharmacy & Health Sciences, 8000 Utopia Parkway, St John’s University, Queens, NY 11439, USA
AuthorAffiliation_xml – name: 1College of Pharmacy & Health Sciences, 8000 Utopia Parkway, St John’s University, Queens, NY 11439, USA
Author_xml – sequence: 1
  givenname: Snehal K
  surname: Shukla
  fullname: Shukla, Snehal K
  organization: College of Pharmacy & Health Sciences, 8000 Utopia Parkway, St John's University, Queens, NY 11439, USA
– sequence: 2
  givenname: Vivek
  surname: Gupta
  fullname: Gupta, Vivek
  organization: College of Pharmacy & Health Sciences, 8000 Utopia Parkway, St John's University, Queens, NY 11439, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31937209$$D View this record in MEDLINE/PubMed
BookMark eNp1kE1PwzAMhiM0xMbYkSvKHygkTdI13NDElzSJCztXSepsQW1aJSnS-PV0KnDDF9vS41fyc4lmvvOA0DUlt5wKcZdqyHJCZUaILM_QIiecZgUh5exnFlKSOVrF-EHG4oRykV-gOaOSrXMiF6jdJde4L-f32CvfJTAH3zXd_ohThwOYoYegEuDYBWXBO41tF3AzjLxR3kDAKYBKLfh0j81BNQ34PUSsfI3tkIYAeEyIPZjkPuEKnVvVRFj99CXaPT2-b16y7dvz6-ZhmxnGWcpUXRRCry3RWheClhI0E0roGkBbbgVjlKxLLW3BCAXNJafcQCFKToQqjGZLlE25JnQxBrBVH1yrwrGipDqZq0Zz1clcdTI38jcT3w-6hfqP_vU0AnICpp-icTA-X03beOGM8_BP-Dft0YHe
CitedBy_id crossref_primary_10_1016_j_molliq_2020_113936
crossref_primary_10_1016_j_onano_2022_100103
crossref_primary_10_1016_j_ijbiomac_2020_05_146
crossref_primary_10_1007_s11095_020_02790_3
crossref_primary_10_1016_j_ijpharm_2020_120117
Cites_doi 10.1517/17460441.2015.1006194
10.2147/NSA.S49052
10.1186/s11671-017-2420-2
10.1208/s12248-012-9339-4
10.1111/j.1365-2141.2012.09139.x
10.1186/s40169-017-0175-0
10.1097/JTO.0000000000000693
10.1016/j.molmed.2015.01.001
10.1038/bjc.2011.244
10.1016/j.powtec.2015.04.044
10.1016/j.ijpharm.2019.03.008
10.1007/s40262-014-0137-2
10.1200/JCO.2009.26.1321
10.1016/j.ijpharm.2019.05.064
10.1016/j.addr.2013.09.017
10.1016/j.lungcan.2017.09.007
10.1007/s10637-017-0538-9
10.1186/s12885-016-2463-2
ContentType Journal Article
Copyright 2020 Newlands Press
Copyright_xml – notice: 2020 Newlands Press
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.4155/tde-2019-0098
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2041-6008
EndPage 215
ExternalDocumentID 10_4155_tde_2019_0098
31937209
Genre Research Support, Non-U.S. Gov't
Editorial
Research Support, N.I.H., Extramural
GroupedDBID -
0R
1LI
3V.
7X7
8FE
8FH
8FI
8FJ
ABUWG
ACGFS
ADBBV
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BBAFP
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
EBS
F5P
FYUFA
HCIFZ
HZ
LK8
M7P
O9-
PQEST
PQQKQ
PROAC
CGR
CUY
CVF
ECM
EIF
NPM
---
0R~
4.4
AAYXX
ABJNI
ACWKX
AFFYO
ALIPV
CCPQU
CITATION
EJD
H13
HMCUK
HZ~
M4Z
OVD
RPM
TDBHL
TEORI
TFL
TMEDX
TVSSL
UKHRP
ID FETCH-LOGICAL-c343t-ad665b7f0bbb65189eb35a5bdeebf4f5331078b9f6301eb49414ce658405a6cb3
ISSN 2041-5990
IngestDate Thu Sep 12 17:04:49 EDT 2024
Fri Sep 17 21:47:49 EDT 2021
Tue Jan 05 21:38:33 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords pulmonary delivery
formulation approaches
sorafenib
non-small-cell lung cancer (NSCLC)
tyrosine-kinase inhibitor
nanocarriers
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c343t-ad665b7f0bbb65189eb35a5bdeebf4f5331078b9f6301eb49414ce658405a6cb3
PMID 31937209
PageCount 3
ParticipantIDs crossref_primary_10_4155_tde_2019_0098
pubmed_primary_31937209
futurescience_futuremedicine_10_4155_tde_2019_0098
ProviderPackageCode 1LI
PublicationCentury 2000
PublicationDate 2020-04-01
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Therapeutic delivery
PublicationTitleAlternate Ther Deliv
PublicationYear 2020
Publisher Newlands Press Ltd
Publisher_xml – name: Newlands Press Ltd
References e_1_3_2_16_1
e_1_3_2_9_1
e_1_3_2_17_1
e_1_3_2_8_1
e_1_3_2_7_1
e_1_3_2_19_1
e_1_3_2_2_1
e_1_3_2_20_1
e_1_3_2_10_1
e_1_3_2_11_1
e_1_3_2_6_1
e_1_3_2_12_1
e_1_3_2_5_1
e_1_3_2_13_1
e_1_3_2_4_1
e_1_3_2_14_1
e_1_3_2_3_1
e_1_3_2_15_1
Garbuzenko OB (e_1_3_2_18_1) 2014; 11
References_xml – ident: e_1_3_2_2_1
  doi: 10.1517/17460441.2015.1006194
– ident: e_1_3_2_20_1
  doi: 10.2147/NSA.S49052
– ident: e_1_3_2_17_1
  doi: 10.1186/s11671-017-2420-2
– ident: e_1_3_2_15_1
  doi: 10.1208/s12248-012-9339-4
– ident: e_1_3_2_4_1
  doi: 10.1111/j.1365-2141.2012.09139.x
– ident: e_1_3_2_16_1
  doi: 10.1186/s40169-017-0175-0
– ident: e_1_3_2_7_1
  doi: 10.1097/JTO.0000000000000693
– ident: e_1_3_2_14_1
  doi: 10.1016/j.molmed.2015.01.001
– ident: e_1_3_2_5_1
  doi: 10.1038/bjc.2011.244
– ident: e_1_3_2_11_1
  doi: 10.1016/j.powtec.2015.04.044
– ident: e_1_3_2_13_1
  doi: 10.1016/j.ijpharm.2019.03.008
– ident: e_1_3_2_9_1
  doi: 10.1007/s40262-014-0137-2
– ident: e_1_3_2_8_1
  doi: 10.1200/JCO.2009.26.1321
– ident: e_1_3_2_10_1
  doi: 10.1016/j.ijpharm.2019.05.064
– volume: 11
  start-page: 44
  issue: 1
  year: 2014
  ident: e_1_3_2_18_1
  article-title: Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention
  publication-title: Cancer Biol. Med.
  contributor:
    fullname: Garbuzenko OB
– ident: e_1_3_2_19_1
  doi: 10.1016/j.addr.2013.09.017
– ident: e_1_3_2_6_1
  doi: 10.1016/j.lungcan.2017.09.007
– ident: e_1_3_2_12_1
  doi: 10.1007/s10637-017-0538-9
– ident: e_1_3_2_3_1
  doi: 10.1186/s12885-016-2463-2
SSID ssj0000401452
Score 2.260519
SourceID crossref
pubmed
futurescience
SourceType Aggregation Database
Index Database
Publisher
StartPage 213
SubjectTerms Antineoplastic Agents - therapeutic use
Cell Line, Tumor
formulation approaches
Humans
Lung Neoplasms - drug therapy
nanocarriers
Nanotechnology - trends
non-small-cell lung cancer (NSCLC)
pulmonary delivery
sorafenib
Sorafenib - therapeutic use
tyrosine-kinase inhibitor
Title Utilizing nanotechnology to recuperate sorafenib for lung cancer treatment: challenges and future perspective
URI http://dx.doi.org/10.4155/tde-2019-0098
https://www.ncbi.nlm.nih.gov/pubmed/31937209
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdp9zIYY2Nf3UfRw9hLcGfZkmzvbZR1ZaxlkGT0zVjKiYVmTij2S__63VnxV-ig24tJBKc4uh-n353uToy9Ry_Dgcx0oBXoQEqbBiaGIhBGWRtaFxYFhQYuLvX5Qn67UleTiRtkLdWVObG3d9aV_I9WcQz1SlWy_6DZblIcwM-oX3yihvF5Lx0vqtV6dUvOPhrJTdVFyYlQIh-st9QxGaYzVLODcmWanMLvNZ30k7JvpvM2zZwCA6ftvSq-bfNZ022kSZEfVGO2RHbe121Nl7Cm7I4uOD_7VV-vG1I6KwEn7UOpX-utZ6s_UeB6GHGIwkGiSmOYolCKQGX-ms8T6MeQPKUjyyoGCJIjMxkPdtzIF3TuG3OiOqiBagmodCq1Cv191eOm2XubWZdiiM4NTZCjeE7iOYkfsAcRGiQ9iOo0O7akw1U6cOr-mm_HSjN8HL3AiL488n1fdlxlzzFpCMr8CXu88yz4Zw-Tp2wC5TP2u4MIH0OEVxveQ4R3EOEIEU4Q4R4ivIPIJ94DhCNAuAcIHwDkOVucfZmfnge7GzYCG8u4Coql1sokLjTGaCXSDEysCmWWAMZJh66AQAppMqdxHwAjMymkBSKtoSq0NfELdlhuSnjFeCEgdXopEptEMtE2Ew6ZeJSlhY4TEOqIfWgXLt_6Rir5nTo6YtFoWXP_rU01-ZvQS7_23dy4tdAFTNnr-_7uG_awB_tbdljd1PAOCWdljtnB5Y-L4wYzfwA2P4Q3
link.rule.ids 315,783,787,27936,27937
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utilizing+Nanotechnology+to+Recuperate+Sorafenib+for+Lung+Cancer+Treatment%3A+Challenges+and+Future+Perspective&rft.jtitle=Therapeutic+delivery&rft.au=Shukla%2C+Snehal+K&rft.au=Gupta%2C+Vivek&rft.date=2020-04-01&rft.issn=2041-5990&rft.eissn=2041-6008&rft.volume=11&rft.issue=4&rft.spage=213&rft.epage=215&rft_id=info:doi/10.4155%2Ftde-2019-0098&rft.externalDBID=n%2Fa&rft.externalDocID=10_4155_tde_2019_0098
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-5990&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-5990&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-5990&client=summon